当前位置:
X-MOL 学术
›
Cancer Lett.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer.
Cancer Letters ( IF 9.7 ) Pub Date : 2019-12-16 , DOI: 10.1016/j.canlet.2019.12.019 Pilei Si 1 , Jinjin Shi 2 , Pei Zhang 3 , Cao Wang 4 , Haijun Chen 4 , Xuefang Mi 4 , Wenling Chu 4 , Baoping Zhai 1 , Wentao Li 1
Cancer Letters ( IF 9.7 ) Pub Date : 2019-12-16 , DOI: 10.1016/j.canlet.2019.12.019 Pilei Si 1 , Jinjin Shi 2 , Pei Zhang 3 , Cao Wang 4 , Haijun Chen 4 , Xuefang Mi 4 , Wenling Chu 4 , Baoping Zhai 1 , Wentao Li 1
Affiliation
Tumor-targeted drug delivery systems with stimuli-response drug release have been increasingly used to improve the therapeutic efficacy of antitumor drugs. Here, we report a specific molecular recognition activation drug nanoplatform based on specially designed DNA sensor-capped doxorubicin (DOX)-loaded mesoporous silica nanoparticles (MSNs), designated as specific molecular recognition-activated nanoparticle (SMRAN). DNA sensors on the targeted nanoparticles can trigger DOX release through a conformational switch induced by MUC-1. This causes a significant difference in cell viability between breast cancer MCF-7 and normal breast Hs578bst cells (24.8% and 86.0%). In vivo experiments showed that the tumor volume was reduced 1.5-times in the SMRAN treatment group. Compared with that in the DOX group, due to significantly improved tumor accumulation and retention of DOX. The strategy of the MUC-1 activated drug delivery system is expected to provide a new perspective for clinical application.
中文翻译:
基于MUC-1识别的活化药物纳米平台可改善阿霉素在乳腺癌中的化疗。
具有刺激响应药物释放的靶向肿瘤的药物递送系统已被越来越多地用于改善抗肿瘤药物的治疗功效。在这里,我们报告基于专门设计的DNA传感器加盖的阿霉素(DOX)加载的中孔二氧化硅纳米粒子(MSNs)的特定分子识别激活药物纳米平台,称为特定分子识别激活纳米粒子(SMRAN)。靶向纳米颗粒上的DNA传感器可以通过MUC-1诱导的构象转换触发DOX释放。这导致乳腺癌MCF-7与正常乳腺癌Hs578bst细胞之间的细胞存活率有显着差异(分别为24.8%和86.0%)。体内实验表明,SMRAN治疗组的肿瘤体积减少了1.5倍。与DOX小组相比,由于显着改善了肿瘤的积累和DOX的保留。MUC-1活化药物递送系统的策略有望为临床应用提供新的视角。
更新日期:2019-12-17
中文翻译:
基于MUC-1识别的活化药物纳米平台可改善阿霉素在乳腺癌中的化疗。
具有刺激响应药物释放的靶向肿瘤的药物递送系统已被越来越多地用于改善抗肿瘤药物的治疗功效。在这里,我们报告基于专门设计的DNA传感器加盖的阿霉素(DOX)加载的中孔二氧化硅纳米粒子(MSNs)的特定分子识别激活药物纳米平台,称为特定分子识别激活纳米粒子(SMRAN)。靶向纳米颗粒上的DNA传感器可以通过MUC-1诱导的构象转换触发DOX释放。这导致乳腺癌MCF-7与正常乳腺癌Hs578bst细胞之间的细胞存活率有显着差异(分别为24.8%和86.0%)。体内实验表明,SMRAN治疗组的肿瘤体积减少了1.5倍。与DOX小组相比,由于显着改善了肿瘤的积累和DOX的保留。MUC-1活化药物递送系统的策略有望为临床应用提供新的视角。